Agios Pharmaceuticals
AGIOAgios Pharmaceuticals is a commercial-stage biopharmaceutical company specializing in the development and commercialization of small-molecule therapies for rare diseases, with a primary focus on non-cancerous hematological disorders.
Earnings
Next report
Oct 29, 2026 (in a month)Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Agios Pharmaceuticals is a commercial-stage biopharmaceutical company specializing in the development and commercialization of small-molecule therapies for rare diseases, with a primary focus on non-cancerous hematological disorders. The company leverages its expertise in cellular metabolism to target enzyme deficiencies, aiming to establish a standard of care for hemolytic anemias and other metabolic conditions. Its value proposition centers on a first-in-class PK activator franchise and a robust clinical pipeline addressing significant unmet medical needs in rare disease communities.
Agios is a leader in the PK activator space with the first-in-class therapy mitapivat, maintaining full ownership of its lead assets in the U.S. while utilizing strategic partnerships for international commercialization.
FAQ
- What is Agios Pharmaceuticals's market cap?
- Agios Pharmaceuticals (AGIO) has a market capitalization of $2.0B and trades on NASDAQ.
- What is Agios Pharmaceuticals's revenue and profitability?
- Agios Pharmaceuticals generated $98.3M in trailing twelve-month revenue with a net loss of $411.3M, representing a net margin of -418.2%. Gross margin stands at 92.0%, with free cash flow of -$365.3M. The latest reported period is Q2 2026.
- Who are Agios Pharmaceuticals's competitors?
- Agios Pharmaceuticals's key competitors include Incyte Corporation, Vertex Pharmaceuticals Incorporated, BioMarin Pharmaceutical, Inc., and others. These companies compete in similar markets and product categories.
- Who does Agios Pharmaceuticals partner with?
- Agios Pharmaceuticals's notable partners include Alnylam Pharmaceuticals, Inc., Servier Pharmaceuticals, LLC, Royalty Pharma, and others.
- Where is Agios Pharmaceuticals headquartered?
- Agios Pharmaceuticals is headquartered in United States of America and employs approximately 386 people. It has been publicly traded since 2013.
